[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy
Metrics: PDF 1971 views | HTML 1672 views | ?
Sarah M. Schwarzenböck1,2, Anna Knieling2,*, Michael Souvatzoglou1,3, Jens Kurth2, Katja Steiger4, Matthias Eiber1, Irene Esposito4,5, Margitta Retz6, Hubert Kübler6, Jürgen E. Gschwend6, Markus Schwaiger1, Bernd J. Krause1,2, Mark Thalgott6
1Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany
2Department of Nuclear Medicine, Rostock University Medical Centre, 18057 Rostock, Germany
3Department of Nuclear Medicine, Ulm University, 89081 Ulm, Germany
4Institute of Pathology, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany
5Institute of Pathology, Heinrich-Heine University of Düsseldorf, 40225 Düsseldorf, Germany
6Department of Urology, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany
Sarah M. Schwarzenböck, email: [email protected]
Keywords: prostate cancer, therapy response assessment, neoadjuvant therapy, choline, PET/CT
Received: March 08, 2016 Accepted: August 24, 2016 Published: August 27, 2016
Purpose: Recent studies have shown promising results of neoadjuvant therapy in prostate cancer (PC). The aim of this study was to evaluate the potential of [11C]Choline PET/CT in therapy response monitoring after combined neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high risk PC patients.
Results: In [11C]Choline PET/CT there was a significant decrease of SUVmax and SUVmean (p = 0.004, each), prostate volume (p = 0.005) and PSA value (p = 0.003) after combined neoadjuvant therapy. MRI showed a significant prostate and tumor volume reduction (p = 0.003 and 0.005, respectively). Number of apoptotic cells was significantly higher in prostatectomy specimens of the therapy group compared to pretherapeutic biopsies and the control group (p = 0.02 and 0.003, respectively).
Methods: 11 patients received two [11C]Choline PET/CT and MRI scans before and after combined neoadjuvant therapy followed by radical prostatectomy and pelvic lymph node dissection. [11C]Choline uptake, prostate and tumor volume, PSA value (before/after neoadjuvant therapy) and apoptosis (of pretherapeutic biopsy/posttherapeutic prostatectomy specimens of the therapy group and prostatectomy specimens of a matched control group without neoadjuvant therapy) were assessed and tested for differences and correlation using SPSS.
Conclusions: The results showing a decrease in choline uptake after combined neoadjuvant therapy (paralleled by regressive and apoptotic changes in histopathology) confirm the potential of [11C]Choline PET/CT to monitor effects of neoadjuvant therapy in locally advanced and high risk PC patients. Further studies are recommended to evaluate its use during the course of neoadjuvant therapy for early response assessment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.